Biospecifics Technologies is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum (CCH). Co. maintains intellectual property with respect to injectable CCH that treats, among other indications, Dupuytren's contracture (DC), Peyronie's disease (PD), frozen shoulder syndrome, and uterine fibroids. Injectable CCH is approved and marketed under the trademark XIAFLEX® for the treatment of both DC and PD. Co. is evaluating CCH as a treatment for uterine fibroids. Under its license agreement with Endo International plc's (Endo), Endo has the right to develop CCH for frozen shoulder and plantar fibromatosis, and other licensed indications. We show 45 historical shares outstanding datapoints in our coverage of BSTC's shares outstanding history.
Understanding the changing numbers of BSTC shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like BSTC versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching BSTC by allowing them to research BSTC shares outstanding history
as well as any other stock in our coverage universe. |
Free BSTC Email Alerts:
Video: Shares Outstanding Importance
